Results 61 to 70 of about 1,440 (183)
The massive exome sequencing reveals new molecular targets in blastic plasmacytoid dendritic cell neoplasm (BPDCN) [PDF]
, 2016 La neoplasia Blastica di derivazione dagli elementi Dendritici Plasmacitoidi è una rara ed aggressiva neoplasia ematologica con una prognosi sfavorevole.
Melle, Federica <1987>
core +1 more source
, 2023 Background BPDCN is a rare, aggressive hematologic malignancy derived from the precursors of plasmacytoid dendritic cells (pDC), typically presenting with primary cutaneous dissemination and involvement of bone marrow (BM) as well as extramedullary sites
Attardi, Enrico +32 more
core +1 more source
Cutaneous involvement by myeloid leukaemias: challenging cases with important implications
Histopathology, EarlyView.Myeloid leukaemias and precursors involving the skin are often challenging to diagnose with varied and overlapping clinical and histopathologic features. Nonetheless, they are critical for pathologists to recognize and accurately classify. This review discusses the clinical, histopathological and genetic features of myelodysplasia cutis (A) and ...
Alexandra C. Hristov
wiley +1 more source
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm
Therapeutic Advances in Hematology, 2019 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides +2 more
doaj +1 more source
Dermatopathology, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare tumor that affects elderly individuals and presents a poor prognosis. Skin is the most common site of involvement, accounting for 89% of the cases.
Phanitchanat Phusuphitchayanan +6 more
doaj +1 more source
ICSH Guidance on Bone Marrow Examination and Reporting
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber +6 more
wiley +1 more source
, 2021 Nowotwór z blastycznych plazmocytoidnych komórek dendrytycznych (BPDCN) jest rzadkim i agresywnym nowotworem hematologicznym. Choroba zwykle zajmuje skórę, szpik kostny, krew obwodową oraz — rzadziej — węzły chłonne.
Kluge, Przemysław; Zakład Diagnostyki Laboratoryjnej, Mazowiecki Szpital Onkologiczny w Wieliszewie +4 more
core
Immunology, EarlyView.Human plasmacytoid dendritic cell‐based vaccines efficiently migrate from blood to lymph nodes and prime naive T cells in humanised mice. Irradiation‐induced CD62L shedding, mediated by p38 MAP kinase and ADAM17, is involved in the regulation of PDC migration to secondary lymphoid organs in this model.
Estelle Leplus +11 more
wiley +1 more source
The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo +5 more
wiley +1 more source
Cytometry Part B: Clinical Cytometry, Volume 110, Issue 5, Page 326-334, September 2026.Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean +2 more
wiley +1 more source